Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy

Supportive Care in Cancer

Volumn 19, Issue 4, 2011, Pages 497-504

  Chan, Alexandre ^a,b   Fu, Wing Hang ^a   Shih, Vivianne ^b   Coyuco, Jurja Chua ^a   Tan, Sze Huey ^b,c   Ng, Raymond ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

Breast cancer; Colony stimulating factors; Cyclophosphamide; Docetaxel; Febrile neutropenia; G CSF

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; ASIAN; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; COHORT ANALYSIS; CONTROLLED STUDY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPHIL COUNT; OBSERVATIONAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; RISK REDUCTION;

EID: 84984586743     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-010-0843-8     Document Type: Article

References (29)

1. Iannucci A, Chan A Management and treatment of hematologic toxicities. In: Ignoffo RJ, Viele C, Ngo Z (eds) Oncology nursing-pharmacy handbook, 1st edn. Elsevier-Mosby
2. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258-2266 (Pubitemid 43673249)
3. Smith TJ, Khatcheressian J, Lyman GH et al (2006) Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187-3205 (Pubitemid 46638957)
4. Lyman GH (2005) Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. J Natl Compr Canc Netw 3:557-571
5. Kuderer NM, Dale DC, Crawford J, Lyman GH (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25:3158-3167 (Pubitemid 47218066)
6. Sung L, Nathan PC, Alibhai SMH, Tomlinson GA, Beyene J (2007) Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med 147:400-411 (Pubitemid 351664541)
7. Lyman GH, Kuderer NM, Djulbegovic B (2002) Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med 112:406-411 (Pubitemid 34246271)
8. Aapro MS, Cameron DA, Pettengell R et al (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42:2433-2453 (Pubitemid 44442936)
9. Jones SE, Savin MA, Holmes FA et al (2006) Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24:5381-5387 (Pubitemid 46623169)
10. Jones S, Holmes FA, O'Shaughnessy J et al (2009) Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 27(8):1177-1183
11. Hor SY, Lee SC, Wong CI et al (2008) PXR, CAR and HNF4? genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients. Pharmacogenomics 8:139-146
12. Segal BH, Freifeld AG, Baden LR et al (2008) Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw 6:122-174 (Pubitemid 351340523)
13. Jenkins P, Freeman S (2009) Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer. Ann Oncol 20(1): 34-40
14. Zou G (2004) A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 159 (7):702-706
15. Cheung YB (2007) A modified least-squares regression approach to the estimation of risk difference. Am J Epidemiol 166 (11):1337-1344
16. Soong D, Haj R, Leung MG et al (2009) High rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide. J Clin Oncol 27(26):e101-e102
17. Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak A (2007) Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev
18. Verschraegen CF, Sittisomwong T, Kudelka AP et al (2000) Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma. J Clin Oncol 18:2733-2739 (Pubitemid 30463556)
19. Martin M, Lluch A, Segui MA et al (2006) Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5- fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 17:1205-1212 (Pubitemid 44288210)
20. Vogel CL, Wojtukiewicz MZ, Carroll RR et al (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23:1178-1184 (Pubitemid 46202274)
21. Nabholtz JM, Falkson C, Campos D et al (2003) Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 21:968-975 (Pubitemid 46594123)
22. Van Cutsem E, Moiseyenko VM, Tjulandin S et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V25 study group. J Clin Oncol 24:4991-4997 (Pubitemid 46631401)
23. Jones SE, Erban J, Overmoyer B et al (2005) Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23:5542-5551
24. Goh BC, Lee SC, Wang LZ et al (2002) Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 20:3683-3690
25. Alexandre J, Rey E, Girre V et al (2007) Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study. Ann Oncol 18:168-172 (Pubitemid 46152518)
26. Tsai SM, Lin CY, Wu SH et al (2009) Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms. Clin Chim Acta. doi:10.1016/j.cca.2009.03.038
27. Hughes WT, Armstrong D, Bodey GP et al (2002) Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730-751 (Pubitemid 34194843)
28. Papaldo P, Lopez M, Marolla P et al (2005) Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J Clin Oncol 23:6908-6918
29. Wilson-Royalty M, Lawless G, Palmer C, Brown R (2001) Predictors for chemotherapy-related severe or febrile neutropenia: a review of the clinical literature. J Oncol Pharm Pract 7:141-147 (Pubitemid 34649658)